tbuckley/cabot-search huggingface dataset:
In-Hospital Mortality in Patients with ESRD Undergoing Hemodialysis Admitted with COVID-19 Compared to Those Without COVID-19
Authors: Laura Aponte Becerra, Jhoan B. Rozas, Carlos A. Torres, Patrick Francois, Juanly N. Rodriguez, Juan D. Salcedo Betancourt, Abraham Santana Rodriguez, Maria Ortiz, Alessia Fornoni, Gabriel Contreras, Jair Munoz Mendoza
Journal: Journal of the American Society of Nephrology (2021)

Background: Patients with end-stage renal disease (ESRD) undergoing chronic hemodialysis (HD) have higher cardiovascular and infection-related death compared to the general population. ESRD patients have many of the comorbidities associated with COVID-19-related death, are at increased risk for severe COVID-19, and have higher COVID-19-related mortality. Whether patients with ESRD and COVID-19 have higher in-patient mortality than patients with ESRD without COVID-19 is unknown. Methods: Retrospective chart review of hospital admissions due to COVID-19 infection or those with ESRD admitted for any other reason between March to June 2020. We collected data on demographics, comorbidities, hospital length of stay, ICU utilization, and mortality. We categorized patients in three groups: ESRD with COVID-19, ESRD without COVID-19, and COVID-19 without ESRD. Mortality analysis was performed using Pearson's Chi-Square and logistic regression analysis. Results: A total of 494 patients with a mean age of 64 years were included, of which 55% were males, 33% were African American, 55% were Hispanic, 49% had hypertension, and 49% had diabetes. 20 patients had ESRD with COVID-19, 195 had ESRD without COVID-19, and 279 had COVID-19 without ESRD. The crude in-hospital mortality rate was 25% in patients with ESRD and COVID-19, 18% in patients with ESRD without COVID19, and 15% in those with COVID-19 without ESRD (p=0.465 for all comparisons). In multivariable logistic regression analyses, the adjusted odds ratio [OR] for in-hospital mortality in patients with ESRD with COVID-19 was 1.46 [95% confidence interval (CI), 0.77-2.80], the OR in patients with ESRD without COVID19 was 1.02 [95% CI, 0.73-1.42], as compared to patients with COVID-19 without ESRD. Conclusions: In-hospital mortality in patients with ESRD with COVID-19 is higher but not significantly different than in patients with ESRD without COVID-19 or than in those with COVID19 without ESRD. Further studies should evaluate the long-term COVID-19-related mortality in patients with ESRD.
Inhibiting bridge integrator 2 phosphorylation leads to improved oocyte quality, ovarian health and fertility in aging and after chemotherapy in mice
Authors: Feng-Yu Zhu, Li-Li Wang, Tie-Gang Meng, Ruo-Lei Wang, Zhi-Xia Yang, Ying Cao, Gang-Yi Zhu, Zhen Jin, Lei-Lei Gao, Wen-Tao Zeng, Zhen-Bo Wang, Qing-Yuan Sun, Dong Zhang
Journal: Nature Aging (2021)
The Natural History of Lower Risk MDS: Factors Predicting Progression to High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia in Patients with Very Low and Low Risk MDS According to the R-IPSS Criteria
Authors: Akriti G Jain, Somedeb Ball, Luis E. Aguirre, Najla Al Ali, David Kaldas, Sara Tinsley-Vance, Andrew T. Kuykendall, Onyee Chan, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman, Rami S. Komrokji
Journal: Blood (2021)
Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma
Authors: Alex Iukuridze, Jennifer Berano Teh, Justin Ramos, Teresa Cabrera Vera, Kyuwan Lee, Rusha Bhandari, Andrew S. Artz, Elizabeth Budde, Alex F. Herrera, Leslie L. Popplewell, Geoffrey Shouse, Tanya Siddiqi, Stephen J Forman, Lennie Wong, Saro H. Armenian
Journal: Blood (2021)
Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci for childhood acute lymphoblastic leukemia
Authors: Soyoung Jeon, Adam J. de Smith, Shaobo Li, Minhui Chen, Tsz Fung Chan, Ivo S. Muskens, Libby M. Morimoto, Andrew T. DeWan, Nicholas Mancuso, Catherine Metayer, Xiaomei Ma, Joseph L. Wiemels, Charleston W. K. Chiang
Journal: Leukemia (2021)
Abstract 11144: Mitral Valve Leaflet Strains Are Unphysiologically Altered After Mitraclip to Repair Functional Mitral Regurgitation
Authors: Brooks A Lane, Dongyang Xu, Muralidhar Padala
Journal: Circulation (2021)

Introduction: Transcatheter edge-to-edge repair (TEER) by approximating the leaflet edges with the MitraClip system ( Fig. A ) is rapidly gaining momentum as the primary therapy for repair of functional mitral regurgitation. Though effective acutely, the unphysiological mechanics that TEER imposes on the valve can be substantial and effect durability of the repair. In this study, we used stereo digital image correlation (sDIC) to quantify the leaflet strains that TEER imposes on the mitral valve in the repair of FMR. Hypothesis: TEER imposes an unphysiological diastolic and early systolic strain on the mitral valve leaflets, which may be associated with poor long-term outcomes. Methods: MVs with intact papillary muscles (PMs) were isolated from porcine hearts and mounted within an acrylic left ventricle chamber. A speckle pattern was imprinted on the valve leaflet surface and a sDIC system with two high-speed cameras imaging at 250 fps recorded synchronized image sequences upon pressurization of the chamber to 120 mm Hg in three different configurations: baseline/healthy, FMR/tethered valve configuration, and with TEER/MitraClip. Results: FMR configuration ( Fig. A2 ) did not alter the peak systolic leaflet strains but elevated the diastolic leaflet strains. The time to peak strain was delayed as well in the FMR configuration. TEER reduced the overall systolic strains on the leaflet from the disease state, but the diastolic strains were further elevated compared to FMR condition. Sub-regional analysis depicted that the leaflet edge section where the TEER was applied was under constantly high strain throughout the cardiac cycle, without an unloading phase. Conclusions: TEER imposes a supraphysiological strain field on the mitral valve leaflet when used to repair FMR. The impact of such strains is not yet known, but may be associated with leaflet remodeling and the 2% of the procedures in which single leaflet detachment has been reported.
Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial
Authors: Juan Pablo Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier Luigi Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Journal: Blood (2021)
A Missense Mutation (R723H) in the Head Motor Domain of β-MYH7 gene in an Indian HCM Patient and Phenotypic Plasticity
Authors: Deepa Selvi Rani, Gnana Veera Subhashini, Ambure Sharadhadevi, Emmanuel Cyril, Kumarasamy Thangaraj
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Mutations in the β-MYH7 gene are one of the major causes that lead to cardiomyopathies. However, to differentiate a causative nsSNP and its impact on protein structure remains a major challenge. In the present study, we detected a missense mutation Arg723His in the head motor domain of β-MYH7 in a HCM patient, and it was absent in 207 healthy individuals. The mutant (R723H) has been found to alter an evolutionarily conserved amino acid. In addition, the mutant (R723H) was predicted pathogenic by Polyphen-2 and SIFT bioinformatic tools. Further, the superimposed 3D structure of the mutant (p.His723 homology model) with native (p. Arg723) displayed the root means square deviation (RMSD) of ~3.38A0. We know that the non-covalent interactions such as hydrophobic, electrostatic, Van der Waals, and hydrogen bonds between amino acids are at the heart of stabilizing protein structures. Here, we demonstrated how the mutant (p.His723) has disrupted a critical non-covalent interactions network at the mutation site and may contribute to the disease phenotype. Hence, our findings in the future could pave the way for developing small molecular modulators or myosin-targeted therapies for heart failure.
Early Mortality and Aggressive Presentation Lead to Poor Outcomes in Patients with Newly Diagnosed Double Hit and Triple Hit Multiple Myeloma
Authors: Charanpreet Singh, Sreejesh Sreedharanunni, Vandana Panakkal, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra
Journal: Blood (2021)
Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors
Authors: Jakub Svoboda, Hatcher J Ballard, Carrie I Ho, Mitchell E. Hughes, Elise A Chong, Adam Duca, Sara Prischak, Sunita Dwivedy Nasta, Marco Ruella, Daniel J Landsburg, Stefan K. Barta, James N Gerson, Stephen J. Schuster
Journal: Blood (2021)
Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents
Authors: Giovanni Marconi, Anna Candoni, Roberta di Nicola, Chiara Sartor, Sarah Parisi, Mariachiara Abbenante, Jacopo Nanni, Gianluca Cristiano, Davide Lazzarotto, Maria Benedetta Giannini, Carmen Baldazzi, Maria Chiara Fontana, Lorenza Bandini, Emanuela Ottaviani, Nicoletta Testoni, Chiara Di Giovanni Bezzi, Rania Abd-alatif, Renato Fanin, Giovanni Martinelli, Stefania Paolini, Michele Cavo, Cristina Papayannidis, Antonio Curti
Journal: Blood (2021)
Early Immune Reconstitution after Hematopoietic Stem Cell Transplantation for Adolescents and Adults with Sickle Cell Disease
Authors: Loïc Vasseur, Florence Morin, Corinne Pondarré, Florian Chevillon, Aude-Marie Fourmont, Regis Peffault De Latour, Nicolas Boissel, Hélène Moins-Teisserenc, Sophie Caillat-Zucman, Nathalie Dhedin
Journal: Blood (2021)
Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome : A Single-Center Retrospective Study
Authors: Kunhwa Kim, Kelly S. Chien, Faustine Ong, Tapan M. Kadia, Elias J. Jabbour, Yesid Alvarado, Koji Sasaki, Carlos E. Bueso-Ramos, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Xiao Qin Dong, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2021)
Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation
Authors: Daisy Diaz Rohena, Janani Ravikrishnan, Chaomei Liu, Guangrong Zheng, Daohong Zhou, Peiyi Zhang, William G. Wierda, Nitin Jain, Jennifer A. Woyach, Deepa Sampath
Journal: Blood (2021)
Tom Nolan’s research reviews—19 November 2021
Authors: Tom Nolan
Journal: BMJ (2021)

No surprises for PfizerThe phase II/III double-blind randomised controlled trial of Pfizer's BNT162b2 vaccine in 5-11 year olds has been published in NEJM. 1 It contains another classic covid incidence-versus-time graph, where the placebo arm ascends like an alpine pass and the BNT162b2 arm has the gentle ascent of a stroll in Norfolk.The authors report a vaccine efficacy of 90.7% for preventing symptomatic covid-19, when two 10 µg vaccine doses were administered 21 days apart.Over the median 2.3 month follow-up period, no serious adverse events related to the vaccine were observed among the 1450 vaccinated children, and no cases of myocarditis-although the study wasn't powered to detect potential rare side effects.On 29 October, the vaccine received emergency use authorisation from the Food and Drug Administration (FDA) to be administered to 5-11 year olds based on these findings.
Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience
Authors: Julius Christoph Enssle, Sebastian Wolf, Sebastian Scheich, Sarah Weber, Michael Kramer, Leo Ruhnke, Christoph Schliemann, Jan-Henrik Mikesch, Stefan W. Krause, Tim Sauer, Maher Hanoun, Hans Christian Reinhardt, Sabrina Kraus, Martin Kaufmann, Mathias Haenel, Lars Fransecky, Andreas Burchert, Andreas Neubauer, Martina Crysandt, Edgar Jost, Dirk Niemann, Kerstin Schäfer-Eckhard, Gerhard Held, Ulrich Kaiser, Maxi Wass, Markus Schaich, Carsten Müller-Tidow, Uwe Platzbecker, Claudia D. Baldus, Martin Bornhäuser, Christoph Rollig, Hubert Serve, Björn Steffen
Journal: Blood (2021)
Multi-task vision transformer using low-level chest X-ray feature corpus for COVID-19 diagnosis and severity quantification
Authors: Sangjoon Park, Gwanghyun Kim, Yujin Oh, Joon Beom Seo, Sang Min Lee, Jin Hwan Kim, Sungjun Moon, Jae-Kwang Lim, Jong Chul Ye
Journal: Medical Image Analysis (2021)
Annals Consult Guys - Talking to Our Patients About Preventing Firearm Injury: Redux
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2021)

Web ExclusivesNovember 2021Annals Consult Guys - Talking to Our Patients About Preventing Firearm Injury: ReduxFREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this author and Howard H. Weitz, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W20-0027 CME/MOC SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This episode of Annals Consult Guys returns to the topic of what physicians can do to help their patients reduce the risk for firearm injury, a growing public health issue in the United States.For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Thomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Disclosures: Geno J. Merli, MD, and Howard H. Weitz, MD, report that they have no financial relationships or interests to disclose.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Stephanie Chang, MD, MPH, Deputy Editor, reports employment with the Agency for Healthcare Research and Quality, travel compensation from the Guidelines International Network, and participation in the Patient-Centered Outcomes Research Institute methodology committee. Vineet Chopra, MD, MSc, Deputy Editor, reports grants received from the Agency for Healthcare Research and Quality and royalties from UpToDate and Oxford University Press. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interests to disclose. Eliseo Guallar, MD, MPH, DrPH, Deputy Editor, Statistics, reports that he has no financial relationships or interests to disclose. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center and consultancy with Boston Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports employment with the Perelman School of Medicine, University of Pennsylvania, and consultancies with the U.S. Food and Drug Administration and the State of Colorado. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics November 2021Volume 174, Issue 11Page: CG1 ePublished: 16 November 2021 Issue Published: November 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.Loading ...
Treatment Outcome and Efficacy of Therapeutic Plasma Exchange for Transplant-Associated Thrombotic Microangiopathy in a Real-World Large Cohort Study
Authors: Li-Ping Yang, Peng Zhao, Ye-Jun Wu, Hai-Xia Fu, Yun He, Xiao-Dong Mo, Meng Lv, Feng-Rong Wang, Chen-Hua Yan, Yu-Hong Chen, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang
Journal: Blood (2021)
Early Cytomegalovirus Reactivation after Allogenic Bone Marrow Transplantation Is Associated with the Loss of Recipient-Derived Humoral Immunity and Is Reduced By IL-6 Inhibition
Authors: Ping Zhang, Peter Fleming, Christopher Andoniou, Jose Paulo Martins, Alda Saldan, Rachel Kuns, Benjamin McEnroe, Andrea S Henden, Stuart Olver, Adaeze Ekwe, Antiopi Varelias, Corey Smith, Christine R Schmidt, Kathleen S Ensbey, Michael Boeckh, Glen A Kennedy, Mariapia Degli-Esposti, Geoff R. Hill, Siok-Keen Tey
Journal: Blood (2021)
Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Zoster Vaccine
Authors: Christopher Pleyer, Kerry J Laing, Mir Ali, Christopher L McClurkan, Susan Soto, Inhye E. Ahn, Pia Nierman, Emeline Maddux, Jennifer Lotter, Jeanine Superata, Xin Tian, Erika M Gaglione, Adrian Wiestner, Jeffrey Cohen, David M Koelle, Clare Sun
Journal: Blood (2021)
Treatment with the Recombinant SLIT2 Protein Delays AML Leukemogenesis In Vivo
Authors: Luise A de Albuquerque Simoes, Isabel Weinhäuser, Diego A Pereira-Martins, César Alexander Ortiz Rojas, Thiago Mantello Bianco, Rita de Cassia Cavaglieri, Eduardo M Rego
Journal: Blood (2021)
Abstract 9202: Sudden Cardiac Death and Icd Use in Rasopathy-Associated Hypertrophic Cardiomyopathy: An International Multi-Centre Study
Authors: Aine Lynch, Sachin Ahuja, Myriam Lafreniere-Roula, Vivian Zhao, Kathryn Armstrong, Pete Aziz, Lee N Benson, Ryan J Butts, Steven D Colan, Andreea Dragulescu, Letizia Gardin, Justin Godown, Heather T Henderson, Emilie M Jean-st-michel, Aamir Jeewa, Paul F Kantor, Beth D Kaufman, Virginie Beausejour-Ladouceur, Ashwin K Lal, John J Parent, Marc E Richmond, Mark W Russell, Seshadri Balaji, Elizabeth A Stephenson, Chet Villa, Robert Whitehill, Jennifer Conway, Taylor Howard, Stephanie J Nakano, Joseph Rosanno, Robert G Weintraub, Seema Mital
Journal: Circulation (2021)

Introduction: Sudden cardiac death (SCD) burden in RASopathy patients (pts) with hypertrophic cardiomyopathy (RAS-HCM) is not known. We compared SCD events and transplant-free survival in RAS versus primary HCM (P-HCM) pts. Methods: The international 22-center retrospective cohort study (PRIMaCY) included 190 pediatric RAS-HCM and 568 P-HCM pts. The primary outcome was 10-year freedom from SCD events (composite of SCD, resuscitated sudden cardiac arrest, and appropriate shock from a prophylactic ICD), estimated using Kaplan Meier method. Results: Of 190 RAS-HCM pts, 82% had Noonan syndrome. Age at diagnosis was lower in RAS-HCM vs P-HCM (0.9 vs 9.7 yrs, p&lt;0.001). There was no difference in baseline LV posterior wall or septal thickness, but LVOT gradient was higher in RAS-HCM vs P-HCM (30 vs 13mmHg, p&lt;0.001). However, frequency of myectomy was not different in RAS-HCM vs P-HCM (15.2% vs 16.7%, p=0.55). Eighteen RAS-HCM pts died (4 SCD, 2 bradycardic arrests, 5 heart failure, 3 respiratory failure, 2 other) with lower 10-year transplant-free survival in RAS-HCM vs P-HCM (84.2% vs 91.6%, p=0.026). Although 10-year cumulative proportion of SCD events was lower in RAS-HCM than P-HCM (5.4% vs 15.1% respectively, p&lt;0.001) (Figure 1), the median age at event was not different (12yrs in RAS-HCM vs 15.2yrs in P-HCM). Of 5 RAS-HCM pts with a SCD event, 4 died and 1 received a secondary prevention ICD. An additional 10 pts received a prophylactic ICD with no appropriate shock during follow-up. The 10-year cumulative proportion of prophylactic ICD was lower at 6.3% in RAS-HCM vs 27.2% in P-HCM (p&lt;0.001). Conclusion: Transplant-free survival was lower in RAS-HCM than P-HCM with mortality related primarily to non-SCD events. Of the RAS-HCM patients with SCD events, 4 died without an ICD highlighting the need for better risk prediction models for both SCD and heart failure mortality in this population.
An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective
Authors: Tycel Phillips, Kristen Migliaccio-Walle, Kristina S. Yu, Brian Bloudek, Nicholas Liu, Michelle A. Fanale, John M. Burke
Journal: Blood (2021)
Redo Mitral Valve Replacement using St. Jude Medical Mechanical Prostheses in a Patient with Degenerated Mitral Perimount Bioprosthesis: A Video Presentation
Authors: Ujjwal Kumar Chowdhury, Niwin George, Lakshmi Kumari Sankhyan, Shikha Goja, Shweta Sharma, Niraj Nirmal Pandey, Srikant Sharma, Shweta Sharma
Journal: Clinical Cardiology and Cardiovascular Interventions (2021)

Current consensus guidelines of the American Heart Association and European Society of Cardiology, uniformly recommend either type of prosthetic mitral valve for patients aged 60 to 70 years, and mechanical prosthesis for patients less than 60 years.
Dynamic Stromal Changes in Myelofibrosis Patients Pre/Post JAK Inhibition Is Revealed in Clinically Archived Bone Marrow Biopsies By Smooth Muscle Actin (SMA)-CD34 Dual Immunohistochemistry
Authors: Katelyn Wang, Iran Rashedi, James T. England, Rashmi S. Goswami, Larissa Liontos, Raheem Peerani, Anne Tierens, Michael J Rauh, Vikas Gupta, Hubert Tsui
Journal: Blood (2021)
Abstract 9431: Preoperative Serum Gdf-15, Endothelin-1 Levels, and Intraoperative Factors as Short-Term Operative Risks for Patients Undergoing Cardiovascular Surgery
Authors: Takashi Kato, Toshiaki Nakajima, Taira Fukuda, IKUKO SHIBASAKI, Toshiyuki Kuwata, Shigeru Toyoda, Teruo Inoue, Hirotsugu Fukuda
Journal: Circulation (2021)

Introduction: The Society of Thoracic Surgeons (STS) risk score is widely used for the risk assessment of cardiac surgery. Serum biomarkers such as growth differentiation factor-15 (GDF-15) and endothelin-1 (ET-1) are also used to evaluate risk. Hypothesis: To investigate the relationships between preoperative serum GDF-15, ET-1 levels, and intraoperative factors and short-term operative risks including acute kidney injury (AKI) for patients undergoing cardiovascular surgery. Methods: Total 145 patients were included in this study (92 males and 53 females, age 68.4 ± 13.2 years). The preoperative STS score was determined, and the serum GDF-15 and ET-1 levels were measured by Enzyme-Linked Immunosorbent Assay. These were related to postoperative risks, including AKI, defined according to the Acute Kidney Injury Network (AKIN) classification criteria. Results: AKI developed in 23% of patients. The GDF-15 and ET-1 levels correlated with the STS score. The STS score and GDF-15 and ET-1 levels all correlated with preoperative eGFR, Alb, Hb, and BNP levels; perioperative data (urine output); ICU stay period; and postoperative admission days. Patients with AKI had longer circulatory pulmonary bypass (CPB) time, and male patients with AKI had higher ET-1 levels than those without AKI. The risk of developing AKI increased with increasing preoperative ET-1 level at baseline (OR for 1 pg/mL increase in ET-1, 2.177; 95% CI, 1.034-4.584; p = 0.041) and CPB time (OR for 1 h increase in CPB time, 4.194; 95% CI, 2.005-8.773; p &lt; 0.001), even adjusted by age, sex, and BMI. In addition, multivariable logistic regression analysis showed that the risk of 30-day mortality plus morbidity increased with increasing preoperative GDF-15 level at baseline, CPB time, and RCC transfusion, even adjusted for age, gender, and BMI. Conclusion: The present study provides evidence that preoperative GDF-15 and ET-1 levels as well as intraoperative factors such as CPB time may be helpful to identify short-term operative risk for patients undergoing cardiovascular surgery.